Firastotug Biosimilar - Research Grade

Human

CTLA4

>1mg/ml

IgG1 - kappa

CHO Cells

Ipilimumab Biosimilar - Research Grade (ICH4025), Tremelimumab Biosimilar - Research Grade (ICH5184), Botensilimab Biosimilar - Research Grade (ICH5412), Evalstotug Biosimilar - Research Grade (ICH5538), Gotistobart Biosimilar - Research Grade (ICH5583), Muzastotug Biosimilar - Research Grade (ICH5696), Nurulimab Biosimilar - Research Grade (ICH5717), Quavonlimab Biosimilar - Research Grade (ICH5794), Sovipostobart Biosimilar - Research Grade (ICH5879), Tazlestobart Biosimilar - Research Grade (ICH5904), Tuvonralimab Biosimilar - Research Grade (ICH5951), Vilastobart Biosimilar - Research Grade (ICH5979), Zalifrelimab Biosimilar - Research Grade (ICH5998)

https://www.imgt.org/mAb-DB/

ICH3002

P16410

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of firastotug, a fully human IgG1-kappa monoclonal antibody directed against human cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, UniProt P16410). It is supplied for research use only and is not the clinical drug; it is not intended for human or veterinary use. Built around the CTLA-4 target, the antibody is useful as a well-characterized reference reagent for benchmarking anti-CTLA-4 binding and blocking activity, as a positive control in checkpoint-blockade assays, and as a comparator in immuno-oncology screening workflows. It supports in-vitro and preclinical studies of T-cell co-stimulation, regulatory T-cell biology, and antibody-dependent effector mechanisms, and can serve as a tool for ADCC/ADC-development and Fc-engineering investigations. The antibody is manufactured to research grade with low endotoxin (<1 EU/mg research grade; <0.5 EU/mg ultra-low endotoxin options) and is available in bulk quantities from milligram to gram scale, making it suitable for high-throughput assay development, in-vitro standards, and reproducible batch-to-batch comparisons. CTLA-4 (CD152) is an inhibitory immune checkpoint receptor expressed by activated conventional T cells and constitutively by regulatory T cells (Tregs). It is a close homolog of the co-stimulatory receptor CD28 and competes with CD28 for the shared B7 ligands CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells, binding them with substantially higher avidity. By outcompeting CD28 and physically removing B7 ligands from APC surfaces via trans-endocytosis, CTLA-4 dampens the co-stimulatory "second signal" required for full T-cell activation, thereby raising the threshold for T-cell priming and enforcing peripheral tolerance. Treg-expressed CTLA-4 is central to their suppressive function. Loss of CTLA-4 causes lethal lymphoproliferation in mice, underscoring its role as a non-redundant negative regulator. Antibody blockade of CTLA-4 releases this brake, enhancing T-cell priming and anti-tumor immunity.

Cytotoxic T-lymphocyte-associated antigen 4, Cytotoxic T-lymphocyte protein 4, CD152

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks